DNMT Inhibitors Market
Number of pages: 100 | Report Format: PDF | Published date: April 13, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 995.31 million |
|
Market Size Value in 2031 |
US$ 3,534.14 million |
|
CAGR |
14.1% |
|
Base Year For Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Application, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global DNMT inhibitors market was valued at US$ 995.31 million in 2022 and is expected to register a revenue CAGR of 14.1% to reach US$ 3,534.14 million by 2031.
DNMT Inhibitors Market Fundamentals
DNA methyltransferase (DNMT) inhibitors are medications used to check the function of DNA methylation in various tissues and model systems. These substances provide a potential therapeutic approach for diseases that entail altered DNA methylation. Clinical trials are now being conducted to determine the effectiveness of DNMT inhibitors in cancer treatment. Preclinical research on their use has produced encouraging findings that influence the global DNMT inhibitors industry trends. DNMT inhibitors' use in treating hematologic and myelodysplastic disorders is also being investigated. The U.S. Food and Drug Administration (FDA) has approved two DNMT inhibitors, azacytidine, and decitabine (5 aza 2' deoxycytidine). The only epigenetic drugs authorized for treating individuals with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are these two medications, the first compounds to be categorized as archetypal DNMT inhibitors.
[86555]
DNMT Inhibitors Market Dynamics
The increased cancer patient pool is the major factor behind the increased global DNMT inhibitors market size. Cancer incidence has climbed globally, surpassing cardiovascular diseases as the second greatest cause of death. According to the stats provided by WHO, the most common causes of cancer death in 2020 were lung cancer, responsible for 1.80 million deaths; colon and rectum, for 916,000; and liver cancer, causing 830,000 deaths. Cancer is caused by environmental variables such as cigarette use, altered dietary habits, urbanization, and prolonged post-reproductive lifetime. The increased sedentary lifestyle among people influences the occurrence of cancer, which accounts for a sizable revenue growth in the global DMNT inhibitor market during the forecast period.
Additionally, advancements in medical science have allowed for improved treatment for cancer, which has contributed to the increase in the DNMT inhibitors market share. Also, the aging population has contributed to the rise in global DNMT inhibitors market growth. On the other hand, chemotherapy is frequently used as the first-line treatment for cancer and has serious side effects such as loss of hair, infections, and anemia. For these reasons, patients choose DNMT inhibitors as an alternative to chemotherapy because they are comparably more effective and cause less cytotoxicity. The global population's increased acceptance and growing awareness of these therapeutics support the demand for DNMT inhibitors.
Furthermore, the factors boosting the global DNMT inhibitors market size are strong pipeline drugs and rising R&D efforts. Around the world, 70 DNMT pipeline drugs are under development, of which azacytidine, decitabine, clofarabine, and arsenic trioxide have been approved for treating hematological cancers. Sixteen pipelines have already completed the clinical research phase; some have even started the phase III clinical investigation. A few DNMT inhibitors for anti-tumor research have reached the clinical stage.
However, studies on the precise side effects and cytotoxicity of DNMT inhibitors are currently lacking. Developing these inhibitors as possible therapeutic medicines for cancer treatment may be hampered by the lack of knowledge. Also, the lack of awareness among patients is the major global DNMT inhibitors market challenge. Therefore, more study is required to fully comprehend their efficacy and safety.
DNMT Inhibitors Market Ecosystem
This report provides the global DNMT inhibitors market analysis regarding revenue growth, market dynamics, regional landscape, and overall competitive positioning of the major market players. The global DNMT inhibitors market is analyzed from four perspectives: type, application, distribution channel, and region.
DNMT Inhibitors Market by Type
Based on the types, the global DNMT inhibitors market is segmented into nucleoside inhibitors and non-nucleoside inhibitors.
According to their structure and mode of action, DNMT inhibitors are categorized as either analog nucleoside antagonists or non-nucleoside inhibitors. While non-nucleoside inhibitors attach to the enzyme and stop the activity of the enzyme, nucleoside analog inhibitors imitate the structure of nucleotides and incorporate it into DNA. These inhibitors have demonstrated excellent outcomes in preclinical research and clinical trials, showing their promise as a cutting-edge therapeutic strategy for cancer treatment.
The nucleoside DNMT inhibitors, including azacytidine, decitabine, zebularine, are the most frequently used cancer therapeutics. Azacytidine, cytarabine derivative of nucleoside DNMT inhibitor, has received FDA and EMA approval for treating chronic myelomonocytic leukemia (CMML). Research is ongoing to investigate the possibility of azanucleosides as a component of combination therapy because they have demonstrated encouraging outcomes in treating other malignancies, such as solid tumors. Azacytidine and decitabine are currently being evaluated in phase 1 clinical studies in patients with solid tumors. Therefore, therapeutic usage of DNMT inhibitors may offer new and efficient treatments for patients with hematological malignancies and other tumor types. Zebularine, a cytidine analog, is the third unique nucleoside DNMT inhibitor family member. It has been described as a potent and promising agent due to successful in vitro tests, which support the usage of zebularine in upcoming clinical trials. As zebularine has a longer half-life than azacytidine and decitabine, cancer cells may be exposed to it for longer. Compared to other DNMT inhibitors, zebularine has been proven to have fewer harmful side effects.
Nevertheless, only a handful of non-nucleoside DNMT inhibitors have been discovered until now, and even fewer have been confirmed to be effective against cancer. Some of the non-nucleoside inhibitors include curcumin, mithramycin, and flavonoids. The use of non-nucleoside DNMT inhibitors in treating several cancers, including lung, breast, and colon cancer, has produced encouraging results. These DNMT inhibitors may be less cytotoxic because they are non-nucleosides and are occasionally preferred by doctors because they do not require active cell division to function. Such inhibitors might offer a viable substitute for or addition to currently available nucleoside-based treatments. The drawbacks of nucleoside-based therapies, such as drug resistance and toxicity, may be solved by non-nucleoside DNMT inhibitors, making them an appealing choice for cancer treatment.
DNMT Inhibitors Market by Application
[92556]
Based on the applications, the global DNMT inhibitors market is segmented into cancer, neurological disorders, genetic disorders, and others. The cancer is further sub-segmented into colon cancer, ovarian cancer, and lung cancer.
The cancer segment accounted for the largest revenue share of the global DNMT inhibitors market in 2022. The global burden of cancer is increasing as a result of rising alcohol and cigarette use, which is fueling the growth of the segment. The World Health Organization predicted that by 2030, there would be over twenty-one million new instances of cancer per year, making it one of the major causes of death globally. Therefore, effective preventative and therapeutic strategies are urgently required to deal with this mounting burden. The market is anticipated to rise due to increased government and non-profit programs to raise awareness about cancer prevention. The most crucial factors driving the demand for alternative treatments are the rising use of chemotherapy and its severe side effects. In the upcoming years, it is also projected that the increasing demand for personalized treatment alternatives will aid in the DNMT inhibitors market growth.
DNMT Inhibitors Market by Distribution Channel
Based on the distribution channel, the global DNMT inhibitors market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies segment accounted for the largest revenue share of the global DNMT inhibitors market in 2022. Hospital pharmacies frequently offer access to specialist drugs unavailable in retail pharmacies and a wider range of prescription drugs. Also, hospital pharmacies have the resources and greater medication management experience to deal with more complicated medical issues. Additionally, hospital pharmacies frequently collaborate closely with medical professionals to guarantee that patients receive the best care. Hospital pharmacies tend to have stronger connections with pharmaceutical companies and can bargain lower pricing for specialized medications such as DNMT inhibitors, making them more affordable for patients.
On the other hand, hospitals are the ideal choice for cancer therapy since they have access to all types of cutting-edge treatments, including DNMT inhibitors. This can enhance patient outcomes and lower the chance of negative effects. Furthermore, despite a patient's financial situation, hospital pharmacies have enough funding and access to subsidized medications to offer the latest cancer care treatment. This guarantees that patients get the care they need without facing financial hardship, which can enhance their overall quality of life. Additionally, hospitals and pharmaceutical firms can work together to undertake clinical trials and research that creates fresh and improved treatment alternatives for cancer.
DNMT Inhibitors Market by Region
Based on the region, the global DNMT inhibitors market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounted for the largest revenue share of the global DNMT Inhibitors market in 2022. This is ascribed to the modern healthcare infrastructure, widespread accessibility of innovative epigenetics products, extensive presence of major companies, and availability of qualified medical personnel. Due to the existence of top manufacturers and supportive healthcare facilities for such treatments, North America dominates the DNMT inhibitors market. This region has high research and development spending on pharmaceuticals related to epigenetics, which complements the anticipated market DNMT inhibitors market size. Additionally, the DNMT inhibitors market demand in North America is expected to increase due to the region's increased rates of cancer and chronic illnesses. However, expensive DNMT inhibitors and strict regulatory requirements may limit commercial expansion.
However, Asia Pacific is expected to account for a rapid revenue growth from 2023 to 2031, which may be attributed to a rise in epigenetics awareness, increased key player coverage in Asia Pacific countries, and the development of infrastructure for research and clinical settings. The DNMT inhibitors market is expected to develop in both areas due to the rising frequency of genetic abnormalities and chronic diseases. Additionally, rising consumer demand for personalized treatments and customized medicine will accelerate market revenue growth.
Competitive Landscape of DNMT Inhibitors Market
Notable market participants operating the global DNMT inhibitors market include,
DNA methyltransferase (DNMT) inhibitors are medications used to research the role of DNA methylation in various tissues and model systems. These substances could be used to treat disorders involving altered DNA methylation.
New treatment strategies and increased cancer prevalence are the key drivers fueling the growth of the global DNMT inhibitors market revenue.
High cost and lack of knowledge about DNMT inhibitors are potentially restricting the revenue growth of the global DNMT inhibitors market.
Key companies operating the global DNMT Inhibitors market are Eisai Inc., Novartis AG, Chroma Medicine, Syndax, and ValiRx Plc.
The global DNMT inhibitors market is expected to grow at a revenue CAGR of 14.1% during the forecast period from 2023 to 2031.
*Insights on financial performance are subject to the availability of information in the public domain